
Urticaria
Latest News
Latest Videos

CME Content
More News

In a real-world setting, omalizumab improved UAS scores, DLQI scores, response scores, and saw a similar or better safety profile.

Researchers compiled best practices for clinicians diagnosing and treating aquagenic urticaria (AU), a rare, but debilitating form of the skin disorder that leaves patients unable to bathe, sweat, or cry without breaking out in painful wheals.

A new study reported no increased incidence of heart disease in patients treated for chronic urticaria, despite prior research highlighting a potential association with other cardiac risk precursors.

Researchers highlight a new set of tests that could streamline the process involved in identifying autoimmune chronic urticaria.

Patients who have either chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU) who take oral corticosteroids (OCS) face a greater risk of side effects as well as higher total healthcare costs, according to a recent study.

When a patient is diagnosed with chronic idiopathic urticaria, there are several things doctors can do to help them. The process to get the proper diagnosis can take several weeks, which can complicate the situation for patients.

People can experience bouts of urticaria over the course of their lives, but usually they only last for a matter of days. When the symptoms last six weeks or more, it can be classified as chronic idiopathic urticaria.

It appears that 300 mg of omalizumab (Xolair/Genentech) is effective in reducing angioedema, according to the results of a new study.

College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.

Clinicians have several guidelines, algorithms, and other tools at their disposal that can assist them in the differential diagnosis and management of chronic urticaria.

















































































